Key Takeaways
- A transition quarter, not a demand problem: Revenue fell to ₹56 crores from ₹90 crores YoY as the old single-customer model ended, while ₹83 crores in one-time costs and upfront team investment pushed adjusted EBITDA to negative ₹16 crores.
- The new model is now live: A nationwide distribution network of 20+ CFAs went operational on 1 October, and the company is building a 900-person field force, so Q3 will be the first quarter reflecting the full inherited portfolio.
- Costs are sized for the future, not the present: Employee costs rose to ₹14 crores from ₹5 crores YoY, and management expects quarterly expenditure to eventually run ₹45–50 crores above the Q1 FY27 base once fully loaded.
- The stabilized base is ~₹600 crores annualized: Management targets quarterly revenue of ~₹150 crores by Q4 FY27 or Q1 FY28, with FY28 revenue growing on a base of around ₹600 crores, and aims to double that organically in 5–6 years plus acquisitions.
- What to watch next quarter: Whether Q3 revenue meaningfully steps up toward the ₹150 crore quarterly target, the pace of MR hiring toward the 900 target, and whether one-time costs stay within the guided ₹15–20 crores.
The Transition: What Broke and What Is Being Built
- Old model ended: The inherited business sold predominantly through a single customer, with limited distribution, minimal field presence, and almost no promotion; ₹41 crores of the prior-year quarter was sales to that one customer.
- New infrastructure built: The company onboarded 20+ CFAs for nationwide last-mile reach, exited global systems and set up independent accounting, HR, and field reporting platforms, and strengthened the board with an independent chair.
- Field force build-out underway: Hiring of experienced people (not freshers) is on track, with frontline managers and area managers structured like leading domestic pharma players; ~300 of the 900 MRs are planned for Minipress promotion.
- Revenue reporting catch-up: Q2 revenue of ₹56 crores does not yet reflect the full portfolio; Q3 will begin reporting all inherited products, but management says Q4 FY27 or Q1 FY28 is the right measure for a stable annualized base.
- Inventory bridge: The company is carrying bridging stock for most products, so real gross margin changes from sourcing efficiencies will be visible only from Q1 FY28 onward because of old inventory and stock already in the market.
Vikas Gupta: "Q2 is the quarter in which the old model ended and a new one began. That brings one-time costs, a one-time correction in revenue and upfront investment in people and systems that goes ahead of the revenue. The important point is that these are transition effects. They do not reflect any change in the underlying demand for our brands."
Portfolio Expansion
- Minipress XL acquisition completed: The market-leading cardiology brand with over 50% market share was acquired from Pfizer, providing entry into cardiology; historically the brand grew at close to 6% against a market growing at around 9%, and management is confident of growing it ahead of the market after the team scales up over one or two quarters.
- Ophthalmology entry: Signed an exclusive distribution and promotion agreement for a retina portfolio (Accentrix and Pagenax), adding innovative products with strong specialist equity.
- Therapy area footprint: Flagship brands now span six priority therapies (cardiology, pain management, wellness, transplant, gynecology, neurosciences) plus ophthalmology.
- Growth levers identified: Organic growth will come from legacy brand growth, brand extensions and lifecycle management, and new product introductions to the same specialties; new launches begin late Q4 or Q1.
Vikas Gupta: "We inherited legendary brands with strong prescriber recall, but there was limited focus and investments in these brands. The majority of the sales was through to a single customer. Further distribution and field presence was limited with hardly any promotion on the brands. So demand rested largely on the loyalty that doctors had built up over the years."
Cost Structure and the Path to Stability
- Employee cost step-up: Employee costs rose to ₹14 crores from ₹5 crores YoY as the company built its own field force and corporate team; management reiterated the team is sized for the future potential of the portfolio, not the current pace.
- Phased cost loading: Employee and selling costs will be stepped up in phases through the second half; Q4 FY27 should show a fully loaded cost structure, with incremental quarterly expenditure of around ₹45–50 crores versus the Q1 FY27 base when fully stable.
- One-time cost tail: Q2 carried ₹83 crores in one-time items (₹68 crores exceptional item from termination of exclusive promotion rights and inventory purchase arrangements, plus ₹15 crores in transition and Minipress XL acquisition-related costs); Q3 may see another ₹15–20 crores, with the cost structure stabilizing by Q4 FY27.
- Finance cost trajectory: Q3 FY27 finance cost expected at ~₹15 crores, Q4 FY27 at ₹10–15 crores; debt to be significantly reduced by 31 March 2027 via a rights issue.
Vikas Gupta: "As we said in our September call, our team is sized for the future potential of the portfolio, not for today's pace."
Revenue Runway and Growth Ambition
- Stabilized quarterly revenue: Management expects ~₹150 crores per quarter once stabilized (Q4 FY27 or Q1 FY28), implying an annualized base of ~₹600 crores.
- FY28 revenue: Expected to be more than ₹600 crores, growing on the stabilized base.
- Organic growth target: Double the ~₹600 crore base organically over the next 5 to 6 years, with acquisitions adding on top.
- IPM context: Management believes industry growth over the long range has been within 8–10% and should remain in that range, with volume growth traditionally around 3–4%.
- Acquisition appetite: The company wants to be very acquisitive going forward, but opportunistic, pursuing deals only where there is financial prudence and strategic synergy; the balance sheet will not carry very high leverage.
Vikas Gupta: "We want to move from a stable business to a business that grows above the market. From a portfolio concentrated in a few flagship brands to a broader basket with regular in-licensing acquisitions and new launches. From a single standalone asset to a platform that grows through disciplined M&A. And from cash sitting on the balance sheet to a business focused on growth, ROCE and free cash flow."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Field force completion | All ~900 MRs on board (including ~300 for Minipress) | By end of Q3 or beginning of Q4 FY27 |
| One-time costs | Another ₹15–20 crores in Q3; cost structure stabilized thereafter | Q3 FY27; stabilized by Q4 FY27 |
| Stabilized quarterly revenue | ~₹150 crores per quarter | Q4 FY27 or Q1 FY28 |
| FY28 revenue | More than ₹600 crores | FY28 |
| Gross margin improvement | Real changes from sourcing efficiencies visible | Q1 FY28 onward |
| New product introductions | Brand extensions and new products for same specialists | Late Q4 FY27 or Q1 FY28 |
| Debt reduction | Significantly reduced via rights issue | By 31 March 2027 |
| Organic growth ambition | Double the ~₹600 crore stabilized base | Over next 5–6 years |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue from operations | ₹56 cr, compared with ₹90 cr in Q2 FY26, of which ₹41 cr was sales to a major customer |
| Half-yearly revenue | ₹160 cr, against ₹178 cr in H1 FY26 |
| Employee costs | ₹14 cr, up from ₹5 cr in Q2 FY26 |
| Other expenses | ₹11 cr, almost flat on Q2 FY26 after excluding one-off expenses |
| Adjusted operating EBITDA | negative ₹16 cr |
| Half-year adjusted operating EBITDA | ₹19 cr |
| Exceptional item | ₹68 cr, comprising ₹61 cr from termination of exclusive promotion rights and related inventory purchase arrangements with one large customer |
| One-off expenses (within other expenses) | ₹15 cr, relating to transition and acquisition-related cost of Minipress XL |
| Total one-time items | ₹83 cr |
| Expected one-time costs in Q3 FY27 | ₹15 cr to ₹20 cr |
| Stabilized annualized revenue base | close to around ₹600 cr, post-inheritance and in-licensing of brands |
| Organic growth target | double the base in 5 to 6 years |
| Target MR strength | 900, with planned hiring completion by end of Q3 FY27 or early Q4 FY27 |
| Planned MRs for Minipress XL | ~300 out of the 900 |
| Minipress XL market share | more than 50% |
| Minipress XL amortization period | 20 to 25 years |
| Expected finance cost Q3 FY27 | ~₹15 cr |
| Expected finance cost Q4 FY27 | ₹10 cr to ₹15 cr |
| Stabilized quarterly revenue run-rate indicator | around ₹150 cr per quarter |
| FY28 revenue guidance | more than ₹600 cr, growing on a stabilized base of around that number |